John Zebala News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes

/PRNewswire/ Syntrix Pharmaceuticals today announced results from a single-arm, open-label Phase 1 trial of single-agent SX-682, an investigational CXCR1/2.

United statesDavid sallmanAaron schulerJohn zebalaH lee moffitt cancer centerSyntrix pharmaceuticalsAmerican society of hematologyResearch instituteInternational prognostic scoring systemNational heartBlood institutePrnewswire syntrix pharmaceuticalsOral sessionMeeting supportPromising targetPatients treated

Combination of Experimental Drug Classes Shown to Extend Survival in Mice with Lung Cancer

Combination of Experimental Drug Classes Shown to Extend Survival in Mice with Lung Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Navire pharmaYuan haoDavidh coganAnne murnick coganKayla guidryGregory williamsCynthia loomisBenjaming neelCarmine fedeleAnsun biopharmaJames christensenShuai liJayu jenAlireza khodadadi jamayranPeter olsonJohn zebala